Home » Healthcare » Pharmaceuticals » Wilson’s Disease Drugs Market

Wilson’s Disease Drugs Market By Indication (Hepatic, Neuropsychiatric, Ophthalmic And Others), By Drug Class (Chelators, Minerals, Pipeline Analysis) , By Drug Type (Copper-Chelating Agents, Zinc Supplements) By Copper-Chelating Agents (Trientine, Penicillamine, Tetrathiomolybdate) – Size, Share, Growth, Trends and Segment Forecasts to 2018-2028

Summary
Table Of Content

Market Insights

The global demand for wilson’s disease drugs was valued at USD 652.8 Million in 2022 and is expected to reach USD 886.55 Million in 2030, growing at a CAGR of 3.9% between 2023 and 2030.
The copper-chelating agent’s drug type dominates the global need for wilson’s disease drugs, accounting for more than 58% in 2022 and is predicted to expand at a high CAGR.
The penicillamine segment is the market leader in copper-chelating agents, accounting for more than 42% of total value in 2022, while the trientine segment is likely to grow rapidly in the estimated period.
The pediatric patients are predicted to grow fastest over the projection period, while the adult patients segment has a market share of more than 60% in 2022.
Over the projection period, the early-stage wilson’s disease category is expected to expand at the highest rate, while the advanced-stage wilson’s disease category dominates the market in 2022 with a 62% share.
The hospitals and clinics segment dominates the global need for wilson’s disease drugs, accounting for more than 45% in 2022 and is predicted to expand at a high CAGR.
The short-term treatment category is expected to expand quickly over the forecast period, while the long-term treatment duration segment has the greatest market share in 2022.
North America is driving the growth of the wilson’s disease drugs industry with over one-third share in 2022, while Asia Pacific and Europe collectively account for just under 55% share in 2022. Europe held over 22% share in 2022.
The rising prevalence of wilson’s disease, a rare genetic disorder affecting copper metabolism, fuels the global demand for effective drug treatments.
Wilson’s illness is present worldwide, with a predicted prevalence of one case per 30,000 live births in most nations, and one in every 90 people possesses a defective copy of the ATP7B gene, which causes the condition.
Continuous research efforts to develop targeted therapies and improved drug delivery mechanisms positively impact wilson’s disease drugs market growth.

Executive Summary

Market Definition

Wilson’s disease is a rare genetic condition characterised by copper buildup in various organs, particularly the liver and brain. The wilson’s disease drugs market is the area of the pharmaceutical industry that focuses on the research, development, manufacturing, and distribution of drugs and therapies designed to diagnose, treat, and manage wilson’s disease. These drugs aim to regulate copper levels in the body, alleviate symptoms, and prevent organ damage caused by copper buildup, enhancing the quality of life for individuals affected by this condition.

Market Overview

The global wilson’s disease drugs market has witnessed rapid growth in recent years and is expected to grow at a CAGR of 3.9% between 2023 and 2030. The market was valued at USD 652.8 million in 2022 and is expected to reach USD 886.55 million in 2030.

Wilson’s illness is a rare inherited ailment that causes copper buildup in the liver, brain, and other important organs. Wilson’s illness is most commonly diagnosed between the ages of 5 and 35, although it can affect children and adults. Wilson’s disease symptoms include abdominal pain, exhaustion, jaundice, loss of appetite, difficulties with speaking, swallowing, or physical coordination, and uncontrollable movements or muscle stiffness.

The increasing improvement in techniques used for Wilson’s disease diagnosis and treatment will likely boost market expansion over the anticipated period. For example, according to a paper published in April 2021 by Translational Gastroenterology and Hepatology Journal, various breakthroughs in diagnosis and genetic testing have proven useful in early detection to avert long-term problems of wilson’s illness. Individuals with Wilson’s disease can be identified using a mix of clinical characteristics such as cirrhosis, Kayser Fleischer (KF) rings, neurological abnormalities, and mental health issues such as anxiety and sadness.

Moreover, increased R&D investments by manufacturers, strong pipeline candidates, increased expenditure on establishing healthcare facilities, and growing awareness about disease prevention across emerging regions all contribute to the growth of the wilson’s disease drugs market. However, a lack of awareness and diagnostic facilities connected with wilson’s disease therapy and high treatment costs due to complications limit the expansion of the wilson’s disease drugs industry. On the other hand, increasing government investments in drug discovery and an upsurge in healthcare expenditures are likely to provide lucrative wilson’s disease drugs market opportunities for the industry’s main players.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Segmentation by Drug Type

The zinc supplements drug types are anticipated to exhibit the highest market CAGR in the projected period. Zinc supplements are increasingly recognized for their effectiveness in reducing copper accumulation and are becoming a preferred treatment option.
The copper-chelating agents currently lead the global market share, holding over 58% in 2022. These agents, particularly penicillamine and trientine, are crucial in managing copper accumulation in Wilson’s disease patients.

Segmentation by Copper-Chelating Agents

The trientine segment is expected to post the highest CAGR in the forecasted period. Its growing adoption is attributed to its efficacy and potential advantages in certain patient groups.
The penicillamine segment is leading the market share with over 42% share in 2022. It remains a cornerstone in managing wilson’s disease and is widely used.

Segmentation by Patient Age

During the projection period, the paediatric patient segment is anticipated to expand at the fastest pace, underscoring the significance of early diagnosis and treatment in Wilson’s disease.
In 2022, the adult patient category held most of the market share, with nearly 60%. This indicates the prevalence of wilson’s disease in the adult population.

Segmentation by Disease Severity

The advanced-stage wilson’s disease dominates the global need for wilson’s disease drugs, accounting for more than 62% in 2022 and is predicted to expand at a high CAGR. Advanced-stage cases require more intensive treatment and monitoring.
The remaining demand for wilson’s disease drugs comes from early-stage cases. This highlights the importance of treatment even in less severe disease presentations.

Segmentation by Distribution Channel

Hospitals and clinics emerge as a dominant distribution channel category, accounting for more than 45% of the global demand for wilson’s disease drugs in 2022. Their important function is influenced by the availability of specialised medical treatment and the requirement for careful supervision.
Retail pharmacies and online platforms address the remaining need for wilson’s disease drugs, providing convenience to patients seeking medications for ongoing management.

Segmentation by Treatment Duration

Long-term treatment holds most of the market share at 55% in 2022. This reflects the chronic nature of Wilson’s disease, necessitating continuous medication.
While long-term treatment is prevalent, the short-term treatment segment is expected to grow rapidly in the forecast period, possibly indicating advancements in treatment approaches and improved outcomes.

Segmentation by Region

North America is a remarkably profitable region for industry players in wilson’s disease drugs market, holding over one-third share in 2022. This can be attributed to advanced healthcare infrastructure, high awareness, and robust research & development activities.
Asia Pacific and Europe collectively account for just under 55% share in 2022. Europe, with over 22% share in the same year, reflects a strong market presence driven by established pharmaceutical industries and ongoing drug developments.
The rest of the world, including Latin America, the Middle East, and Africa, contributes to the remaining demand for wilson’s disease drugs, indicating a global need for effective treatments.

The global wilson’s disease drugs market is primarily driven by factors such as the emerging prevalence of wilson’s disease, advancements in diagnostic methods, and growing efforts to improve patient outcomes through effective treatment options.

North America has the largest share of the global wilson’s disease drugs market, with the U.S. contributing the most revenue. The highly advanced regional healthcare infrastructure, strong pharmaceutical industry, and high awareness about rare diseases contribute to its dominant position. Moreover, North America has a significant focus on R&D, leading to the discovery of innovative treatments and therapies for Wilson’s disease. Also, according to PubMed data from 2022, Americans are becoming more likely to experience chronic pain. Each year, one in every five adults in the region suffers from chronic pain. Wilson’s disease drugs are in high demand across the U.S. as it is one of the most prevalent chronic illnesses.

Over the projected period, the Asia Pacific is anticipated to experience the highest growth rate in wilson’s disease drugs market. This growth can be attributed to growing healthcare spending, improving healthcare infrastructure, and raising awareness about rare diseases like wilson’s disease. In addition, the large regional population, growing middle class, and advancements in medical research and treatments are expected to fuel the demand for wilson’s disease drugs in the Asia Pacific region.

The increased demand for early detection and treatment of wilson’s disease and the availability of sophisticated diagnostic technologies are propelling the expansion of the wilson’s disease drugs market. Several governments are promoting early detection and treatment of rare diseases like wilson’s disease.

Various organizations are raising awareness about wilson’s illness, which drives market growth throughout the predicted period. Wilson’s disease association, based in New York, is a volunteer organization committed to promoting the well-being of Wilson’s disease patients by providing up-to-date information on the condition, its symptoms, and treatment.

Key Highlights of the Report

The global wilson’s disease drugs market is segmented by drug type, copper-chelating agents, patient age, disease severity, distribution channels, treatment duration, and region. Copper-chelating agents, particularly penicillamine and trientine, currently dominate the market, while zinc supplements show promising growth potential due to their effectiveness in reducing copper accumulation. In terms of patient demographics, adult patients account for the majority of the market share, but pediatric patients are expected to exhibit the highest growth rate. Disease severity plays a crucial role, with advanced-stage wilson’s disease being the dominant segment. Hospitals and clinics are the primary distribution channels, providing specialized care, while retail pharmacies and online platforms cater to ongoing management needs. Long-term treatment is prevalent, reflecting the chronic nature of the disease, but short-term treatment is poised for rapid growth, signifying evolving treatment approaches.

The growing global prevalence of wilson’s disease, coupled with emerging awareness among healthcare professionals and patients, is accelerating the market growth. Additionally, advancements in medical research and technology are leading to the development of more effective and targeted drug therapies. Moreover, the rising adoption of personalized medicine and precision therapies is opening new avenues for treatment. Furthermore, collaborations between pharmaceutical companies and research institutions are accelerating drug development processes.

North America is expected to hold a substantial market revenue share owing to its advanced healthcare infrastructure, well-established pharmaceutical industry, and increasing prevalence of wilson’s disease cases. The region’s focus on R&D and strong regulatory frameworks contribute to its dominance. Conversely, the Asia-Pacific region presents a promising growth landscape driven by rising healthcare investments, improving healthcare access, and increasing awareness about rare diseases like wilson’s disease. The burgeoning population, advancements in healthcare technologies, and increased healthcare expenditure are anticipated to fuel the market’s expansion in the region.

What Are The Main Drivers Of The Global Wilson’s Disease Drugs Market?

The global wilson’s disease drugs market is primarily driven by factors such as the growing occurrence of wilson’s disease, advancements in diagnostic technologies, and increasing awareness among patients and healthcare professionals. The availability of innovative drug therapies and ongoing R&D activities contribute to expanding treatment options. Supportive regulatory environments for drug approval and the growing emphasis on early disease detection and intervention drive market growth. Moreover, collaborations between pharmaceutical companies and academic institutions and increasing healthcare investments further promote the development and adoption of effective wilson’s disease drugs worldwide.

What Are The Major Challenges Faced By The Global Wilson’s Disease Drugs Market?

The global wilson’s disease drugs market faces several significant challenges, including the relatively low prevalence of the disease, leading to limited patient populations and potential challenges in conducting clinical trials and research. Besides, the complex nature of wilson’s disease and the variability of symptoms among patients can complicate diagnosis and treatment decisions. The high cost of treatment and lack of awareness among healthcare professionals and patients about wilson’s disease and available treatment options hinder the market expansion. Furthermore, potential side effects and adverse reactions associated with some drug therapies may impact patient compliance and treatment outcomes.

What Are The Growth Opportunities In The Global Wilson’s Disease Drugs Market?

The global wilson’s disease drugs market presents several growth opportunities driven by advancements in research and the development of innovative therapies. The growing trend of personalized medicine and precision therapies opens doors for tailored approaches to managing wilson’s disease based on individual patient characteristics. The rising demand for improved patient outcomes and the adoption of gene therapy and targeted therapies offer avenues for market expansion. Moreover, strategic initiatives to expand market presence in emerging economies and develop more cost-effective treatment options can tap into previously untapped market segments.

Market Drivers

Several factors drive the global wilson’s disease drugs market. The following are the key drivers of the global wilson’s disease drugs market:

Increasing Disease Prevalence and Awareness

One of the major drivers of the global wilson’s disease drugs market is the rising prevalence of wilson’s disease, a rare genetic disorder characterized by abnormal copper accumulation in various organs. Wilson’s illness affects around 1 in 30,000 people in the United States, according to the National Organisation for Rare Disorders (NORD), and the disease’s frequency is predicted to rise in the coming years.

As awareness about the disease grows, more patients are being diagnosed and seeking appropriate treatment. Early detection and intervention are important for managing the disease effectively, driving the demand for therapeutic options. This increased recognition and understanding of wilson’s disease among healthcare professionals and patients propelled the market’s growth.

Market Restraints

The global wilson’s disease drugs market faces challenges that may hinder its growth. These include the following:

High Treatment Costs

The higher cost associated with wilson’s disease drugs is a key restraint for the global market. Developing and producing drugs for rare diseases involves significant research & development expenses, which can translate to higher drug prices. Besides, since Wilson’s disease is a chronic condition that requires lifelong treatment, the cumulative cost of medications and ongoing medical management can be substantial. The financial burden on patients, healthcare systems, and insurance providers can hinder access to treatment for some individuals, limiting the market’s potential expansion. High treatment costs also lead to affordability issues, especially in regions with limited healthcare resources, potentially affecting patient compliance and treatment outcomes.

Opportunities

The global wilson’s disease drugs market offers significant growth opportunities. These include the following:

Rising Focus on Rare Diseases and Orphan Drug Developments

The increasing focus on rare diseases and orphan drug development presents a substantial opportunity for the wilson’s disease drugs industry. Regulatory agencies, such as the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA) provide incentives for developing drugs for rare diseases, including expedited review processes, extended exclusivity periods, and financial incentives. Thus, pharmaceutical companies are increasingly investing in the research and development (R&D) of drugs for rare diseases like wilson’s disease. As a result of this tendency, new medicines and treatment alternatives that are particularly created to meet the particular problems presented by uncommon diseases are likely to be discovered.

Competitive Landscape

Key Players

The global wilson’s disease drugs market is highly competitive, with several key players. The following are some of the top market players and their market shares:

ANI Pharmaceuticals Inc
Navinta LLC
Lupin Ltd
Teva Pharmaceutical Industries Ltd
Apotex
Dr. Reddy’s Laboratories Ltd
Breckenridge Pharmaceutical Inc
Bausch Health Companies Inc
Panacea Biotec Ltd
Par Pharmaceutical
Others

These companies focus on research & development activities to introduce novel drugs that improve treatment outcomes. Strategic collaborations, partnerships, and acquisitions are commonly observed strategies to enhance product portfolios and expand market presence. The market is also witnessing efforts to increase awareness among healthcare professionals and patients about the disease and available treatment options. In addition, regulatory approvals and clinical trials play a key role in shaping the market’s competitive dynamics, influencing the positioning and adoption of new therapies.

In December 2017, Wilson Therapeutics AB stated that the U.S. FDA had granted WTX101 Fast Track classification for treating Wilson’s Disease. WTX101 (Bis-choline tetrathiomolybdate) is a copper-protein-binding compound with a novel mechanism of action that is being studied as a novel therapy for Wilson’s Disease.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Summary of Key Findings

Advancements in genetic testing and personalized medicine approaches enhance the precision and effectiveness of drug treatments, leading to better outcomes for patients with wilson’s disease.
Market segmented by drug type, copper-chelating agents, patient age, disease severity, distribution channels, treatment duration, and region.
Copper-chelating agents and zinc supplements are the primary drug types.
The penicillamine segment holds the largest market share in copper-chelating agents, while the trientine segment is projected to grow significantly.
Hospitals and clinics dominate distribution channels, followed by retail pharmacies and online platforms.
Short-term treatment duration is expected to grow rapidly, indicating evolving treatment approaches.
Recent advancements in drug therapies, including chelating agents like penicillamine and newer treatments like trientine and zinc acetate, are expanding the array of treatment options available for wilson’s disease patients.
Market challenges include high treatment costs, limited accessibility in certain regions, and regulatory hurdles.
North America holds a substantial global market share due to advanced healthcare infrastructure and research initiatives.

Future Outlook

The growing awareness and increasing healthcare expenditure in emerging markets offer growth opportunities for expanding the market reach of wilson’s disease drugs.
Patient-centric approaches, such as telemedicine, digital health platforms, and remote monitoring, are expected to gain traction, enhancing patient engagement, adherence, and disease management.
Manufacturers and policymakers are anticipated to navigate evolving pricing dynamics, ensuring that novel therapies remain accessible to patients while allowing sustainable innovation.

Segmentation

By Drug Type
- Copper-Chelating Agents
- Zinc Supplements
By Copper-Chelating Agents
- Trientine
- Penicillamine
- Tetrathiomolybdate
By Patient Age
- Pediatric Patients
- Adult Patients
By Disease Severity
- Early-stage Wilson’s Disease
- Advanced-Stage Wilson’s Disease
By Distribution Channels
- Hospitals and Clinics
- Retail Pharmacies
- Online Pharmacies
By Treatment Duration
- Short-Term Treatment
- Long-Term Treatment
By Region
- North America
  - The U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - France
  - The U.K.
  - Italy
  - Spain
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - South-east Asia
  - Rest of Asia Pacific
- Latin America
  - Brazil
  - Argentina
  - Rest of Latin America
- Middle East & Africa
  - GCC Countries
  - South Africa
  - Rest of the Middle East and Africa

Adjacent Markets

In the wilson’s disease drugs market, several adjacent markets have high revenue growth opportunities. The key adjacent markets for wilson’s disease drugs market –

1. Preface

1.1. Report Description

1.1.1. Purpose of the Report

1.1.2. Target Audience

1.1.3. USP and Key Offerings

1.2. Research Scope

1.3. Market Introduction

2. Executive Summary

2.1. Market Snapshot: Global Wilson’s Disease Drugs Market

2.1.1. Global Wilson’s Disease Drugs Market, By Drug Type

2.1.2. Global Wilson’s Disease Drugs Market, By Copper-Chelating Agents

2.1.3. Global Wilson’s Disease Drugs Market, By Patient Age

2.1.4. Global Wilson’s Disease Drugs Market, By Disease Severity

2.1.5. Global Wilson’s Disease Drugs Market, By Distribution Channels

2.1.6. Global Wilson’s Disease Drugs Market, By Treatment Duration

2.1.7. Global Wilson’s Disease Drugs Market, By Region

2.2. Insights from Primary Respondents

3. Market Dynamics & Factors Analysis

3.1. Introduction

3.1.1. Global Wilson’s Disease Drugs Market Value, 2017-2030, (US$ Mn)

3.1.2. Y-o-Y Growth Trend Analysis

3.2. Market Dynamics

3.2.1. Wilson’s Disease Drugs Market Drivers

3.2.2. Wilson’s Disease Drugs Market Restraints

3.2.3. Wilson’s Disease Drugs Market Opportunities

3.2.4. Major Wilson’s Disease Drugs Industry Challenges

3.3. Growth and Development Patterns

3.4. Investment Feasibility Analysis

3.5. Market Opportunity Analysis

3.5.1. Drug Type

3.5.2. Copper-Chelating Agents

3.5.3. Patient Age

3.5.4. Disease Severity

3.5.5. Distribution Channels

3.5.6. Treatment Duration

3.5.7. Geography

4. Market Competitive Landscape Analysis

4.1. Company Market Share Analysis, 2022

4.1.1. Global Wilson’s Disease Drugs Market: Company Market Share, Value 2022

4.1.2. Global Wilson’s Disease Drugs Market: Top 6 Company Market Share, Value 2022

4.1.3. Global Wilson’s Disease Drugs Market: Top 3 Company Market Share, Value 2022

4.2. Global Wilson’s Disease Drugs Market: Company Revenue Share Analysis, 2022

4.3. Company Assessment Metrics, 2022

4.3.1. Stars

4.3.2. Emerging Leaders

4.3.3. Pervasive Players

4.3.4. Participants

4.4. Startups/ SMEs Assessment Metrics, 2022

4.4.1. Progressive Companies

4.4.2. Responsive Companies

4.4.3. Dynamic Companies

4.4.4. Starting Blocks

4.5. Strategic Development

4.5.1. Acquisition and Mergers

4.5.2. New Product Launch

4.5.3. Regional Expansion

4.5.4. Partnerships

4.6. Key Player Product Matrix

4.7. Potential for New Players in the Global Wilson’s Disease Drugs Market

5. Premium Insights

5.1. STAR (Situation, Task, Action, Results) Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Bargaining Power of Buyers/Consumers

5.2.3. Bargaining Power of Suppliers

5.2.4. Threat of Substitute Types

5.2.5. Intensity of Competitive Rivalry

5.3. PESTEL Analysis

5.3.1. Political Factors

5.3.2. Economic Factors

5.3.3. Social Factors

5.3.4. Technological Factors

5.3.5. Environmental Factors

5.3.6. Legal Factors

5.4. Key Market Trends

5.4.1. Demand Side Trends

5.4.2. Supply Side Trends

5.5. Value Chain Analysis

5.6. Technology Analysis

5.6.1. Research and development in the global market

5.6.2. Patent Analysis

5.6.3. Emerging technologies and their potential disruption to the market

5.7. Consumer Behaviour Analysis

5.7.1. Consumer Preferences and Expectations

5.7.2. Factors Influencing Consumer Buying Decisions

5.7.2.1. North America

5.7.2.2. Europe

5.7.2.3. Asia Pacific

5.7.2.4. Latin America

5.7.2.5. Middle East and Africa

5.7.3. Consumer Pain Points

5.8. Analysis and Recommendations

5.9. Adjacent Market Analysis

6. Market Positioning of Key Players, 2022

6.1. Company market share of key players, 2022

6.2. Competitive Benchmarking

6.3. Market Positioning of Key Vendors

6.4. Geographical Presence Analysis

6.5. Major Strategies Adopted by Key Players

6.5.1. Key Strategies Analysis

6.5.2. Mergers and Acquisitions

6.5.3. Partnerships

6.5.4. Product Launch

6.5.5. Geographical Expansion

6.5.6. Others

7. Impact Analysis of COVID-19 and Russia – Ukraine War on Wilson’s Disease Drugs Market

7.1. Ukraine-Russia War Impact

7.1.1. Uncertainty and Economic Instability

7.1.2. Supply chain disruptions

7.1.3. Regional market shifts

7.1.4. Shift in government priorities

7.2. COVID-19 Impact Analysis

7.2.1. Supply Chain Disruptions

7.2.2. Demand Fluctuations

7.2.3. Shift in Product Mix

7.2.4. Reduced Industrial Activity

7.2.5. Regional Impact Analysis

7.2.5.1. North America

7.2.5.2. Europe

7.2.5.3. Asia Pacific

7.2.5.4. Latin America

7.2.5.5. Middle East and Africa

8. Global Wilson’s Disease Drugs Market, By Drug Type

8.1. Global Wilson’s Disease Drugs Market Overview, by Drug Type

8.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Drug Type, 2022 Vs 2030 (in %)

8.2. Copper-Chelating Agents

8.2.1. Global Wilson’s Disease Drugs Market, By Copper-Chelating Agents, By Region, 2017-2030 (US$ Mn)

8.2.2. Market Dynamics for Copper-Chelating Agents

8.2.2.1. Drivers

8.2.2.2. Restraints

8.2.2.3. Opportunities

8.2.2.4. Trends

8.3. Zinc Supplements

8.3.1. Global Wilson’s Disease Drugs Market, By Zinc Supplements, By Region, 2017-2030 (US$ Mn)

8.3.2. Market Dynamics for Zinc Supplements

8.3.2.1. Drivers

8.3.2.2. Restraints

8.3.2.3. Opportunities

8.3.2.4. Trends

9. Global Wilson’s Disease Drugs Market, By Copper-Chelating Agents

9.1. Global Wilson’s Disease Drugs Market Overview, by Copper-Chelating Agents

9.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Copper-Chelating Agents, 2022 Vs 2030 (in %)

9.2. Trientine

9.2.1. Global Wilson’s Disease Drugs Market, By Trientine, By Region, 2017-2030 (US$ Mn)

9.2.2. Market Dynamics for Trientine

9.2.2.1. Drivers

9.2.2.2. Restraints

9.2.2.3. Opportunities

9.2.2.4. Trends

9.3. Penicillamine

9.3.1. Global Wilson’s Disease Drugs Market, By Penicillamine, By Region, 2017-2030 (US$ Mn)

9.3.2. Market Dynamics for Penicillamine

9.3.2.1. Drivers

9.3.2.2. Restraints

9.3.2.3. Opportunities

9.3.2.4. Trends

9.4. Tetrathiomolybdate

9.4.1. Global Wilson’s Disease Drugs Market, By Tetrathiomolybdate, By Region, 2017-2030 (US$ Mn)

9.4.2. Market Dynamics for Tetrathiomolybdate

9.4.2.1. Drivers

9.4.2.2. Restraints

9.4.2.3. Opportunities

9.4.2.4. Trends

10. Global Wilson’s Disease Drugs Market, By Patient Age

10.1. Global Wilson’s Disease Drugs Market Overview, by Patient Age

10.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Patient Age, 2022 Vs 2030 (in %)

10.2. Pediatric Patients

10.2.1. Global Wilson’s Disease Drugs Market, By Pediatric Patients, By Region, 2017-2030 (US$ Mn)

10.2.2. Market Dynamics for Pediatric Patients

10.2.2.1. Drivers

10.2.2.2. Restraints

10.2.2.3. Opportunities

10.2.2.4. Trends

10.3. Adult Patients

10.3.1. Global Wilson’s Disease Drugs Market, By Adult Patients, By Region, 2017-2030 (US$ Mn)

10.3.2. Market Dynamics for Adult Patients

10.3.2.1. Drivers

10.3.2.2. Restraints

10.3.2.3. Opportunities

10.3.2.4. Trends

11. Global Wilson’s Disease Drugs Market, By Disease Severity

11.1. Global Wilson’s Disease Drugs Market Overview, by Disease Severity

11.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Disease Severity, 2022 Vs 2030 (in %)

11.2. Early-Stage Wilson’s Disease

11.2.1. Global Wilson’s Disease Drugs Market, By Early-Stage Wilson’s Disease, By Region, 2017-2030 (US$ Mn)

11.2.2. Market Dynamics for Early-Stage Wilson’s Disease

11.2.2.1. Drivers

11.2.2.2. Restraints

11.2.2.3. Opportunities

11.2.2.4. Trends

11.3. Advanced-Stage Wilson’s Disease

11.3.1. Global Wilson’s Disease Drugs Market, By Advanced-Stage Wilson’s Disease, By Region, 2017-2030 (US$ Mn)

11.3.2. Market Dynamics for Advanced-Stage Wilson’s Disease

11.3.2.1. Drivers

11.3.2.2. Restraints

11.3.2.3. Opportunities

11.3.2.4. Trends

12. Global Wilson’s Disease Drugs Market, By Distribution Channels

12.1. Global Wilson’s Disease Drugs Market Overview, by Distribution Channels

12.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Distribution Channels, 2022 Vs 2030 (in %)

12.2. Hospitals and Clinics

12.2.1. Global Wilson’s Disease Drugs Market, By Hospitals and Clinics, By Region, 2017-2030 (US$ Mn)

12.2.2. Market Dynamics for Hospitals and Clinics

12.2.2.1. Drivers

12.2.2.2. Restraints

12.2.2.3. Opportunities

12.2.2.4. Trends

12.3. Retail Pharmacies

12.3.1. Global Wilson’s Disease Drugs Market, By Retail Pharmacies, By Region, 2017-2030 (US$ Mn)

12.3.2. Market Dynamics for Retail Pharmacies

12.3.2.1. Drivers

12.3.2.2. Restraints

12.3.2.3. Opportunities

12.3.2.4. Trends

12.4. Online Pharmacies

12.4.1. Global Wilson’s Disease Drugs Market, By Online Pharmacies, By Region, 2017-2030 (US$ Mn)

12.4.2. Market Dynamics for Online Pharmacies

12.4.2.1. Drivers

12.4.2.2. Restraints

12.4.2.3. Opportunities

12.4.2.4. Trends

13. Global Wilson’s Disease Drugs Market, By Treatment Duration

13.1. Global Wilson’s Disease Drugs Market Overview, by Treatment Duration

13.1.1. Global Wilson’s Disease Drugs Market Revenue Share, By Treatment Duration, 2022 Vs 2030 (in %)

13.2. Short-Term Treatment

13.2.1. Global Wilson’s Disease Drugs Market, By Short-Term Treatment, By Region, 2017-2030 (US$ Mn)

13.2.2. Market Dynamics for Short-Term Treatment

13.2.2.1. Drivers

13.2.2.2. Restraints

13.2.2.3. Opportunities

13.2.2.4. Trends

13.3. Long-Term Treatment

13.3.1. Global Wilson’s Disease Drugs Market, By Long-Term Treatment, By Region, 2017-2030 (US$ Mn)

13.3.2. Market Dynamics for Long-Term Treatment

13.3.2.1. Drivers

13.3.2.2. Restraints

13.3.2.3. Opportunities

13.3.2.4. Trends

14. Global Wilson’s Disease Drugs Market, By Region

14.1. Global Wilson’s Disease Drugs Market Overview, by Region

14.1.1. Global Wilson’s Disease Drugs Market, By Region, 2022 vs 2030 (in%)

14.2. Drug Type

14.2.1. Global Wilson’s Disease Drugs Market, By Drug Type, 2017-2030 (US$ Mn)

14.3. Copper-Chelating Agents

14.3.1. Global Wilson’s Disease Drugs Market, By Copper-Chelating Agents, 2017-2030 (US$ Mn)

14.4. Patient Age

14.4.1. Global Wilson’s Disease Drugs Market, By Patient Age, 2017-2030 (US$ Mn)

14.5. Disease Severity

14.5.1. Global Wilson’s Disease Drugs Market, By Disease Severity, 2017-2030 (US$ Mn)

14.6. Distribution Channels

14.6.1. Global Wilson’s Disease Drugs Market, By Distribution Channels, 2017-2030 (US$ Mn)

14.7. Treatment Duration

14.7.1. Global Wilson’s Disease Drugs Market, By Treatment Duration, 2017-2030 (US$ Mn)

15. North America Wilson’s Disease Drugs Market Analysis

15.1. Overview

15.1.1. Market Dynamics for North America

15.1.1.1. Drivers

15.1.1.2. Restraints

15.1.1.3. Opportunities

15.1.1.4. Trends

15.2. North America Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

15.2.1. Overview

15.2.2. SRC Analysis

15.3. North America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

15.3.1. Overview

15.3.2. SRC Analysis

15.4. North America Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

15.4.1. Overview

15.4.2. SRC Analysis

15.5. North America Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

15.5.1. Overview

15.5.2. SRC Analysis

15.6. North America Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

15.6.1. Overview

15.6.2. SRC Analysis

15.7. North America Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

15.7.1. Overview

15.7.2. SRC Analysis

15.8. North America Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

15.8.1. North America Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

15.8.2. U.S.

15.8.3. Canada

15.8.4. Mexico

16. Europe Wilson’s Disease Drugs Market Analysis

16.1. Overview

16.1.1. Market Dynamics for North America

16.1.1.1. Drivers

16.1.1.2. Restraints

16.1.1.3. Opportunities

16.1.1.4. Trends

16.2. Europe Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

16.2.1. Overview

16.2.2. SRC Analysis

16.3. Europe Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

16.3.1. Overview

16.3.2. SRC Analysis

16.4. Europe Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

16.4.1. Overview

16.4.2. SRC Analysis

16.5. Europe Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

16.5.1. Overview

16.5.2. SRC Analysis

16.6. Europe Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

16.6.1. Overview

16.6.2. SRC Analysis

16.7. Europe Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

16.7.1. Overview

16.7.2. SRC Analysis

16.8. Europe Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

16.8.1. Europe Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

16.8.2. UK

16.8.3. France

16.8.4. Germany

16.8.5. Italy

16.8.6. Spain

16.8.7. Benelux

16.8.8. Russia

16.8.9. Rest of Europe

17. Asia Pacific Wilson’s Disease Drugs Market Analysis

17.1. Overview

17.1.1. Market Dynamics for North America

17.1.1.1. Drivers

17.1.1.2. Restraints

17.1.1.3. Opportunities

17.1.1.4. Trends

17.2. Asia Pacific Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

17.2.1. Overview

17.2.2. SRC Analysis

17.3. Asia Pacific Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

17.3.1. Overview

17.3.2. SRC Analysis

17.4. Asia Pacific Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

17.4.1. Overview

17.4.2. SRC Analysis

17.5. Asia Pacific Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

17.5.1. Overview

17.5.2. SRC Analysis

17.6. Asia Pacific Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

17.6.1. Overview

17.6.2. SRC Analysis

17.7. Asia Pacific Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

17.7.1. Overview

17.7.2. SRC Analysis

17.8. Asia Pacific Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

17.8.1. Asia Pacific Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

17.8.2. China

17.8.3. Japan

17.8.4. India

17.8.5. South Korea

17.8.6. South East Asia

17.8.7. Rest of Asia Pacific

18. Latin America Wilson’s Disease Drugs Market Analysis

18.1. Overview

18.1.1. Market Dynamics for North America

18.1.1.1. Drivers

18.1.1.2. Restraints

18.1.1.3. Opportunities

18.1.1.4. Trends

18.2. Latin America Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

18.2.1. Overview

18.2.2. SRC Analysis

18.3. Latin America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

18.3.1. Overview

18.3.2. SRC Analysis

18.4. Latin America Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

18.4.1. Overview

18.4.2. SRC Analysis

18.5. Latin America Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

18.5.1. Overview

18.5.2. SRC Analysis

18.6. Latin America Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

18.6.1. Overview

18.6.2. SRC Analysis

18.7. Latin America Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

18.7.1. Overview

18.7.2. SRC Analysis

18.8. Latin America Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

18.8.1. Latin America Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

18.8.2. Brazil

18.8.3. Argentina

18.8.4. Rest of Latin America

19. Middle East Wilson’s Disease Drugs Market Analysis

19.1. Overview

19.1.1. Market Dynamics for North America

19.1.1.1. Drivers

19.1.1.2. Restraints

19.1.1.3. Opportunities

19.1.1.4. Trends

19.2. Middle East Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

19.2.1. Overview

19.2.2. SRC Analysis

19.3. Middle East Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

19.3.1. Overview

19.3.2. SRC Analysis

19.4. Middle East Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

19.4.1. Overview

19.4.2. SRC Analysis

19.5. Middle East Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

19.5.1. Overview

19.5.2. SRC Analysis

19.6. Middle East Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

19.6.1. Overview

19.6.2. SRC Analysis

19.7. Middle East Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

19.7.1. Overview

19.7.2. SRC Analysis

19.8. Middle East Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

19.8.1. Middle East Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

19.8.2. UAE

19.8.3. Saudi Arabia

19.8.4. Rest of Middle East

20. Africa Wilson’s Disease Drugs Market Analysis

20.1. Overview

20.1.1. Market Dynamics for North America

20.1.1.1. Drivers

20.1.1.2. Restraints

20.1.1.3. Opportunities

20.1.1.4. Trends

20.2. Africa Wilson’s Disease Drugs Market, by Drug Type, 2017-2030(US$ Mn)

20.2.1. Overview

20.2.2. SRC Analysis

20.3. Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2030(US$ Mn)

20.3.1. Overview

20.3.2. SRC Analysis

20.4. Africa Wilson’s Disease Drugs Market, by Patient Age, 2017-2030(US$ Mn)

20.4.1. Overview

20.4.2. SRC Analysis

20.5. Africa Wilson’s Disease Drugs Market, by Disease Severity, 2017-2030(US$ Mn)

20.5.1. Overview

20.5.2. SRC Analysis

20.6. Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2030(US$ Mn)

20.6.1. Overview

20.6.2. SRC Analysis

20.7. Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2030(US$ Mn)

20.7.1. Overview

20.7.2. SRC Analysis

20.8. Africa Wilson’s Disease Drugs Market, by Country, 2017-2030 (US$ Mn)

20.8.1. Middle East Wilson’s Disease Drugs Market, by Country, 2022 Vs 2030 (in%)

20.8.2. South Africa

20.8.3. Egypt

20.8.4. Rest of Africa

21. Company Profiles

21.1. ANI Pharmaceuticals Inc

21.1.1. Company Overview

21.1.2. Products/Services Portfolio

21.1.3. Geographical Presence

21.1.4. SWOT Analysis

21.1.5. Financial Summary

21.1.5.1. Market Revenue and Net Profit (2019-2022)

21.1.5.2. Business Segment Revenue Analysis

21.1.5.3. Geographical Revenue Analysis

21.2. Navinta LLC

21.3. Lupin Ltd

21.4. Teva Pharmaceutical Industries Ltd

21.5. Apotex

21.6. Dr. Reddy’s Laboratories Ltd

21.7. Breckenridge Pharmaceutical Inc

21.8. Bausch Health Companies Inc

21.9. Panacea Biotec Ltd

21.10. Par Pharmaceutical

21.11. Others

22. Research Methodology

22.1. Research Methodology

22.2. Phase I – Secondary Research

22.3. Phase II – Data Modelling

22.3.1. Company Share Analysis Model

22.3.2. Revenue Based Modelling

22.4. Phase III – Primary Research

22.5. Research Limitations

22.5.1. Assumptions

List of Figures

FIG. 1 Global Wilson’s Disease Drugs Market: Research Methodology

FIG. 2 Market Size Estimation – Top Down & Bottom Up Approach

FIG. 3 Global Wilson’s Disease Drugs Market Segmentation

FIG. 4 Global Wilson’s Disease Drugs Market, by Drug Type, 2022 (US$ Mn)

FIG. 5 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2022 (US$ Mn)

FIG. 6 Global Wilson’s Disease Drugs Market, by Patient Age, 2022 (US$ Mn)

FIG. 7 Global Wilson’s Disease Drugs Market, by Disease Severity, 2022 (US$ Mn)

FIG. 8 Global Wilson’s Disease Drugs Market, by Distribution Channels, 2022 (US$ Mn)

FIG. 9 Global Wilson’s Disease Drugs Market, by Treatment Duration, 2022 (US$ Mn)

FIG. 10 Global Wilson’s Disease Drugs Market, by Geography, 2022 (US$ Mn)

FIG. 11 Attractive Investment Proposition, by Drug Type, 2022

FIG. 12 Attractive Investment Proposition, by Copper-Chelating Agents, 2022

FIG. 13 Attractive Investment Proposition, by Patient Age, 2022

FIG. 14 Attractive Investment Proposition, by Disease Severity, 2022

FIG. 15 Attractive Investment Proposition, by Distribution Channels, 2022

FIG. 16 Attractive Investment Proposition, by Treatment Duration, 2022

FIG. 17 Attractive Investment Proposition, by Geography, 2022

FIG. 18 Global Market Share Analysis of Key Wilson’s Disease Drugs Market Manufacturers, 2022

FIG. 19 Global Market Positioning of Key Wilson’s Disease Drugs Market Manufacturers, 2022

FIG. 20 Global Wilson’s Disease Drugs Market Value Contribution, By Drug Type, 2022 & 2030 (Value %)

FIG. 21 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, Value, 2017-2030 (US$ Mn)

FIG. 22 Global Wilson’s Disease Drugs Market, by Zinc Supplements, Value, 2017-2030 (US$ Mn)

FIG. 23 Global Wilson’s Disease Drugs Market Value Contribution, By Copper-Chelating Agents, 2022 & 2030 (Value %)

FIG. 24 Global Wilson’s Disease Drugs Market, by Trientine, Value, 2017-2030 (US$ Mn)

FIG. 25 Global Wilson’s Disease Drugs Market, by Penicillamine, Value, 2017-2030 (US$ Mn)

FIG. 26 Global Wilson’s Disease Drugs Market, by Tetrathiomolybdate, Value, 2017-2030 (US$ Mn)

FIG. 27 Global Wilson’s Disease Drugs Market Value Contribution, By Patient Age, 2022 & 2030 (Value %)

FIG. 28 Global Wilson’s Disease Drugs Market, by Pediatric Patients, Value, 2017-2030 (US$ Mn)

FIG. 29 Global Wilson’s Disease Drugs Market, by Adult Patients, Value, 2017-2030 (US$ Mn)

FIG. 30 Global Wilson’s Disease Drugs Market Value Contribution, By Disease Severity, 2022 & 2030 (Value %)

FIG. 31 Global Wilson’s Disease Drugs Market, by Early-Stage Wilson’s Disease, Value, 2017-2030 (US$ Mn)

FIG. 32 Global Wilson’s Disease Drugs Market, by Advanced-Stage Wilson’s Disease, Value, 2017-2030 (US$ Mn)

FIG. 33 Global Wilson’s Disease Drugs Market Value Contribution, By Distribution Channels, 2022 & 2030 (Value %)

FIG. 34 Global Wilson’s Disease Drugs Market, by Hospitals and Clinics, Value, 2017-2030 (US$ Mn)

FIG. 35 Global Wilson’s Disease Drugs Market, by Retail Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 36 Global Wilson’s Disease Drugs Market, by Online Pharmacies, Value, 2017-2030 (US$ Mn)

FIG. 37 Global Wilson’s Disease Drugs Market Value Contribution, By Treatment Duration, 2022 & 2030 (Value %)

FIG. 38 Global Wilson’s Disease Drugs Market, by Short-Term Treatment, Value, 2017-2030 (US$ Mn)

FIG. 39 Global Wilson’s Disease Drugs Market, by Long-Term Treatment, Value, 2017-2030 (US$ Mn)

FIG. 40 North America Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 41 U.S. Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 42 Canada Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 43 Mexico Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 44 Europe Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 45 Germany Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 46 France Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 47 U.K. Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 48 Italy Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 49 Spain Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 50 Benelux Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 51 Russia Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 52 Rest of Europe Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 53 Asia Pacific Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 54 China Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 55 Japan Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 56 India Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 57 South Korea Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 58 South-East Asia Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 59 Rest of Asia Pacific Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 60 Latin America Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 61 Brazil Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 62 Argentina Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 63 Rest of Latin America Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 64 Middle East Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 65 UAE Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 66 Saudi Arabia Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 67 Rest of Middle East Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 68 Africa Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 69 South Africa Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 70 Egypt Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

FIG. 71 Rest of Africa Wilson’s Disease Drugs Market, 2017-2030 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Wilson’s Disease Drugs Market

TABLE 2 Global Wilson’s Disease Drugs Market: Market Drivers Impact Analysis

TABLE 3 Global Wilson’s Disease Drugs Market: Market Restraints Impact Analysis

TABLE 4 Global Wilson’s Disease Drugs Market, by Competitive Benchmarking, 2022

TABLE 5 Global Wilson’s Disease Drugs Market, by Geographical Presence Analysis, 2022

TABLE 6 Global Wilson’s Disease Drugs Market, by Key Strategies Analysis, 2022

TABLE 7 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, By Region, 2017-2022 (US$ Mn)

TABLE 8 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, By Region, 2023-2030 (US$ Mn)

TABLE 9 Global Wilson’s Disease Drugs Market, by Zinc Supplements, By Region, 2017-2022 (US$ Mn)

TABLE 10 Global Wilson’s Disease Drugs Market, by Zinc Supplements, By Region, 2023-2030 (US$ Mn)

TABLE 11 Global Wilson’s Disease Drugs Market, by Trientine, By Region, 2017-2022 (US$ Mn)

TABLE 12 Global Wilson’s Disease Drugs Market, by Trientine, By Region, 2023-2030 (US$ Mn)

TABLE 13 Global Wilson’s Disease Drugs Market, by Penicillamine, By Region, 2017-2022 (US$ Mn)

TABLE 14 Global Wilson’s Disease Drugs Market, by Penicillamine, By Region, 2023-2030 (US$ Mn)

TABLE 15 Global Wilson’s Disease Drugs Market, by Tetrathiomolybdate, By Region, 2017-2022 (US$ Mn)

TABLE 16 Global Wilson’s Disease Drugs Market, by Tetrathiomolybdate, By Region, 2023-2030 (US$ Mn)

TABLE 17 Global Wilson’s Disease Drugs Market, by Pediatric Patients, By Region, 2017-2022 (US$ Mn)

TABLE 18 Global Wilson’s Disease Drugs Market, by Pediatric Patients, By Region, 2023-2030 (US$ Mn)

TABLE 19 Global Wilson’s Disease Drugs Market, by Adult Patients, By Region, 2017-2022 (US$ Mn)

TABLE 20 Global Wilson’s Disease Drugs Market, by Adult Patients, By Region, 2023-2030 (US$ Mn)

TABLE 21 Global Wilson’s Disease Drugs Market, by Early-Stage Wilson’s Disease, By Region, 2017-2022 (US$ Mn)

TABLE 22 Global Wilson’s Disease Drugs Market, by Early-Stage Wilson’s Disease, By Region, 2023-2030 (US$ Mn)

TABLE 23 Global Wilson’s Disease Drugs Market, by Advanced-Stage Wilson’s Disease, By Region, 2017-2022 (US$ Mn)

TABLE 24 Global Wilson’s Disease Drugs Market, by Advanced-Stage Wilson’s Disease, By Region, 2023-2030 (US$ Mn)

TABLE 25 Global Wilson’s Disease Drugs Market, by Hospitals and Clinics, By Region, 2017-2022 (US$ Mn)

TABLE 26 Global Wilson’s Disease Drugs Market, by Hospitals and Clinics, By Region, 2023-2030 (US$ Mn)

TABLE 27 Global Wilson’s Disease Drugs Market, by Retail Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 28 Global Wilson’s Disease Drugs Market, by Retail Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 29 Global Wilson’s Disease Drugs Market, by Online Pharmacies, By Region, 2017-2022 (US$ Mn)

TABLE 30 Global Wilson’s Disease Drugs Market, by Online Pharmacies, By Region, 2023-2030 (US$ Mn)

TABLE 31 Global Wilson’s Disease Drugs Market, by Short-Term Treatment, By Region, 2017-2022 (US$ Mn)

TABLE 32 Global Wilson’s Disease Drugs Market, by Short-Term Treatment, By Region, 2023-2030 (US$ Mn)

TABLE 33 Global Wilson’s Disease Drugs Market, by Long-Term Treatment, By Region, 2017-2022 (US$ Mn)

TABLE 34 Global Wilson’s Disease Drugs Market, by Long-Term Treatment, By Region, 2023-2030 (US$ Mn)

TABLE 35 Global Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 36 Global Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 37 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 38 Global Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 39 Global Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 40 Global Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 41 Global Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 42 Global Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 43 Global Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 44 Global Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 45 Global Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 46 Global Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 47 Global Wilson’s Disease Drugs Market, by Region, 2017-2022 (US$ Mn)

TABLE 48 Global Wilson’s Disease Drugs Market, by Region, 2023-2030 (US$ Mn)

TABLE 49 North America Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 50 North America Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 51 North America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 52 North America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 53 North America Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 54 North America Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 55 North America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 56 North America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 57 North America Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 58 North America Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 59 North America Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 60 North America Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 61 North America Wilson’s Disease Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 62 North America Wilson’s Disease Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 63 United States Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 64 United States Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 65 United States Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 66 United States Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 67 United States Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 68 United States Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 69 United States Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 70 United States Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 71 United States Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 72 United States Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 73 United States Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 74 United States Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 75 Canada Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 76 Canada Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 77 Canada Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 78 Canada Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 79 Canada Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 80 Canada Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 81 Canada Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 82 Canada Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 83 Canada Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 84 Canada Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 85 Canada Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 86 Canada Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 87 Mexico Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 88 Mexico Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 89 Mexico Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 90 Mexico Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 91 Mexico Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 92 Mexico Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 93 Mexico Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 94 Mexico Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 95 Mexico Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 96 Mexico Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 97 Mexico Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 98 Mexico Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 99 Europe Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 100 Europe Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 101 Europe Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 102 Europe Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 103 Europe Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 104 Europe Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 105 Europe Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 106 Europe Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 107 Europe Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 108 Europe Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 109 Europe Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 110 Europe Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 111 Europe Wilson’s Disease Drugs Market, by Country, 2017-2022 (US$ Mn)

TABLE 112 Europe Wilson’s Disease Drugs Market, by Country, 2023-2030 (US$ Mn)

TABLE 113 Germany Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 114 Germany Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 115 Germany Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 116 Germany Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 117 Germany Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 118 Germany Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 119 Germany Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 120 Germany Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 121 Germany Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 122 Germany Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 123 Germany Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 124 Germany Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 125 France Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 126 France Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 127 France Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 128 France Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 129 France Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 130 France Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 131 France Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 132 France Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 133 France Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 134 France Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 135 France Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 136 France Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 137 United Kingdom Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 138 United Kingdom Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 139 United Kingdom Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 140 United Kingdom Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 141 United Kingdom Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 142 United Kingdom Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 143 United Kingdom Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 144 United Kingdom Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 145 United Kingdom Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 146 United Kingdom Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 147 United Kingdom Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 148 United Kingdom Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 149 Italy Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 150 Italy Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 151 Italy Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 152 Italy Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 153 Italy Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 154 Italy Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 155 Italy Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 156 Italy Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 157 Italy Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 158 Italy Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 159 Italy Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 160 Italy Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 161 Spain Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 162 Spain Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 163 Spain Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 164 Spain Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 165 Spain Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 166 Spain Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 167 Spain Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 168 Spain Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 169 Spain Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 170 Spain Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 171 Spain Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 172 Spain Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 173 Benelux Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 174 Benelux Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 175 Benelux Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 176 Benelux Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 177 Benelux Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 178 Benelux Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 179 Benelux Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 180 Benelux Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 181 Benelux Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 182 Benelux Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 183 Benelux Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 184 Benelux Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 185 Russia Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 186 Russia Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 187 Russia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 188 Russia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 189 Russia Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 190 Russia Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 191 Russia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 192 Russia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 193 Russia Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 194 Russia Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 195 Russia Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 196 Russia Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 197 Rest of Europe Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 198 Rest of Europe Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 199 Rest of Europe Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 200 Rest of Europe Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 201 Rest of Europe Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 202 Rest of Europe Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 203 Rest of Europe Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 204 Rest of Europe Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 205 Rest of Europe Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 206 Rest of Europe Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 207 Rest of Europe Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 208 Rest of Europe Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 209 Asia Pacific Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 210 Asia Pacific Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 211 Asia Pacific Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 212 Asia Pacific Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 213 Asia Pacific Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 214 Asia Pacific Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 215 Asia Pacific Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 216 Asia Pacific Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 217 Asia Pacific Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 218 Asia Pacific Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 219 Asia Pacific Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 220 Asia Pacific Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 221 China Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 222 China Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 223 China Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 224 China Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 225 China Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 226 China Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 227 China Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 228 China Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 229 China Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 230 China Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 231 China Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 232 China Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 233 Japan Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 234 Japan Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 235 Japan Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 236 Japan Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 237 Japan Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 238 Japan Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 239 Japan Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 240 Japan Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 241 Japan Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 242 Japan Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 243 Japan Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 244 Japan Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 245 India Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 246 India Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 247 India Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 248 India Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 249 India Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 250 India Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 251 India Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 252 India Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 253 India Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 254 India Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 255 India Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 256 India Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 257 South Korea Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 258 South Korea Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 259 South Korea Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 260 South Korea Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 261 South Korea Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 262 South Korea Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 263 South Korea Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 264 South Korea Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 265 South Korea Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 266 South Korea Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 267 South Korea Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 268 South Korea Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 269 South-East Asia Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 270 South-East Asia Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 271 South-East Asia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 272 South-East Asia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 273 South-East Asia Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 274 South-East Asia Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 275 South-East Asia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 276 South-East Asia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 277 South-East Asia Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 278 South-East Asia Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 279 South-East Asia Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 280 South-East Asia Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 281 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 282 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 283 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 284 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 285 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 286 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 287 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 288 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 289 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 290 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 291 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 292 Rest of Asia Pacific Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 293 Latin America Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 294 Latin America Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 295 Latin America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 296 Latin America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 297 Latin America Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 298 Latin America Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 299 Latin America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 300 Latin America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 301 Latin America Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 302 Latin America Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 303 Latin America Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 304 Latin America Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 305 Brazil Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 306 Brazil Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 307 Brazil Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 308 Brazil Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 309 Brazil Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 310 Brazil Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 311 Brazil Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 312 Brazil Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 313 Brazil Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 314 Brazil Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 315 Brazil Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 316 Brazil Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 317 Argentina Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 318 Argentina Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 319 Argentina Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 320 Argentina Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 321 Argentina Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 322 Argentina Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 323 Argentina Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 324 Argentina Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 325 Argentina Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 326 Argentina Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 327 Argentina Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 328 Argentina Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 329 Rest of Latin America Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 330 Rest of Latin America Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 331 Rest of Latin America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 332 Rest of Latin America Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 333 Rest of Latin America Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 334 Rest of Latin America Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 335 Rest of Latin America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 336 Rest of Latin America Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 337 Rest of Latin America Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 338 Rest of Latin America Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 339 Rest of Latin America Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 340 Rest of Latin America Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 341 Middle East Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 342 Middle East Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 343 Middle East Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 344 Middle East Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 345 Middle East Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 346 Middle East Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 347 Middle East Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 348 Middle East Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 349 Middle East Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 350 Middle East Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 351 Middle East Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 352 Middle East Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 353 UAE Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 354 UAE Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 355 UAE Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 356 UAE Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 357 UAE Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 358 UAE Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 359 UAE Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 360 UAE Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 361 UAE Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 362 UAE Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 363 UAE Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 364 UAE Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 365 Saudi Arabia Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 366 Saudi Arabia Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 367 Saudi Arabia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 368 Saudi Arabia Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 369 Saudi Arabia Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 370 Saudi Arabia Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 371 Saudi Arabia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 372 Saudi Arabia Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 373 Saudi Arabia Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 374 Saudi Arabia Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 375 Saudi Arabia Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 376 Saudi Arabia Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 377 Rest of Middle East Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 378 Rest of Middle East Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 379 Rest of Middle East Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 380 Rest of Middle East Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 381 Rest of Middle East Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 382 Rest of Middle East Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 383 Rest of Middle East Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 384 Rest of Middle East Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 385 Rest of Middle East Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 386 Rest of Middle East Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 387 Rest of Middle East Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 388 Rest of Middle East Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 389 Africa Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 390 Africa Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 391 Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 392 Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 393 Africa Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 394 Africa Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 395 Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 396 Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 397 Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 398 Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 399 Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 400 Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 401 South Africa Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 402 South Africa Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 403 South Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 404 South Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 405 South Africa Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 406 South Africa Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 407 South Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 408 South Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 409 South Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 410 South Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 411 South Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 412 South Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 413 Egypt Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 414 Egypt Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 415 Egypt Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 416 Egypt Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 417 Egypt Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 418 Egypt Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 419 Egypt Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 420 Egypt Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 421 Egypt Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 422 Egypt Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 423 Egypt Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 424 Egypt Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

TABLE 425 Rest of Africa Wilson’s Disease Drugs Market, by Drug Type, 2017-2022 (US$ Mn)

TABLE 426 Rest of Africa Wilson’s Disease Drugs Market, by Drug Type, 2023-2030 (US$ Mn)

TABLE 427 Rest of Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2017-2022 (US$ Mn)

TABLE 428 Rest of Africa Wilson’s Disease Drugs Market, by Copper-Chelating Agents, 2023-2030 (US$ Mn)

TABLE 429 Rest of Africa Wilson’s Disease Drugs Market, by Patient Age, 2017-2022 (US$ Mn)

TABLE 430 Rest of Africa Wilson’s Disease Drugs Market, by Patient Age, 2023-2030 (US$ Mn)

TABLE 431 Rest of Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2017-2022 (US$ Mn)

TABLE 432 Rest of Africa Wilson’s Disease Drugs Market, by Disease Severity, By Region, 2023-2030 (US$ Mn)

TABLE 433 Rest of Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2017-2022 (US$ Mn)

TABLE 434 Rest of Africa Wilson’s Disease Drugs Market, by Distribution Channels, 2023-2030 (US$ Mn)

TABLE 435 Rest of Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2017-2022 (US$ Mn)

TABLE 436 Rest of Africa Wilson’s Disease Drugs Market, by Treatment Duration, 2023-2030 (US$ Mn)

Frequently Asked Question

What is the current size of the global wilson’s disease drugs market?

The global wilson’s disease drugs market was valued at USD 652.8 Million in 2022.

What is the expected growth rate of the wilson’s disease drugs market between 2023 and 2030?

The wilson’s disease drugs market is expected to grow at a CAGR of 3.9% between 2023 and 2030, reaching USD 886.55 Million in 2030.

Which segment is leading the market share in terms of drug type?

Copper-chelating agents are the leading segment by drug type, holding over 58% share in value in 2022.

Which distribution channel segment governs the global demand for wilson’s disease drugs?

The hospitals and clinics segment governs the global demand for wilson’s disease drugs, holding a massive share of over 45% in 2022.

Which copper-chelating agents segment will post the highest CAGR in the forecast period?

The trientine segment will post the highest CAGR over the projection period.

Which region is fueling the growth of the wilson’s disease drugs industry?

North America is fueling the growth of the wilson’s disease drugs industry, with over one-third share in 2022.

Who are the major players in the global wilson’s disease drugs market?

The top players include ANI Pharmaceuticals Inc, Navinta LLC, Lupin Ltd, Teva Pharmaceutical Industries Ltd, Apotex, Dr. Reddy’s Laboratories Ltd, Breckenridge Pharmaceutical Inc, Bausch Health Companies Inc, Panacea Biotec Ltd, Par Pharmaceutical, and Others.

What are the major market drivers of the wilson’s disease drugs industry?

The major market drivers are the increasing prevalence of wilson’s disease, advancements in drug therapies, and growing awareness about early diagnosis and treatment options.

What are the major market restraints of the wilson’s disease drugs industry?

The major market restraints of wilson’s disease drugs industry include a limited patient pool, higher treatment costs, challenges in accurate diagnosis, and potential side effects associated with existing treatments.

What are the major market opportunities of the wilson’s disease drugs industry?

The major market opportunities of the wilson’s disease drugs industry include untapped emerging markets, the development of novel therapies, and collaborations for R&D of more effective treatment options.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –